218 related articles for article (PubMed ID: 36047857)
1. A stated preference survey to explore patient preferences for novel preventive migraine treatments.
Hubig LT; Smith T; Chua GN; Lloyd AJ; Powell L; Johnston K; Harris L; L'Italien G; Coric V; Lo SH
Headache; 2022 Oct; 62(9):1187-1197. PubMed ID: 36047857
[TBL] [Abstract][Full Text] [Related]
2. Patient preferences for attributes of injected or infused preventive migraine medications: Findings from a discrete choice experiment.
Schwedt TJ; Martin A; Kymes S; Talon B; Lee XY; Cady R; Asher D; Karnik-Henry M; Mulvihill E; Bates D; Beusterien K
Headache; 2023 Apr; 63(4):484-493. PubMed ID: 36753057
[TBL] [Abstract][Full Text] [Related]
3. Patient Preferences for Preventive Migraine Treatments: A Discrete-Choice Experiment.
Mansfield C; Gebben DJ; Sutphin J; Tepper SJ; Schwedt TJ; Sapra S; Shah N
Headache; 2019 May; 59(5):715-726. PubMed ID: 30861110
[TBL] [Abstract][Full Text] [Related]
4. Discrete Choice Experiment to Understand Japanese Patients' and Physicians' Preferences for Preventive Treatments for Migraine.
Seo J; Tervonen T; Ueda K; Zhang D; Danno D; Tockhorn-Heidenreich A
Neurol Ther; 2023 Apr; 12(2):651-668. PubMed ID: 36848008
[TBL] [Abstract][Full Text] [Related]
5. Safety of Rimegepant, an Oral CGRP Receptor Antagonist, Plus CGRP Monoclonal Antibodies for Migraine.
Berman G; Croop R; Kudrow D; Halverson P; Lovegren M; Thiry AC; Conway CM; Coric V; Lipton RB
Headache; 2020 Sep; 60(8):1734-1742. PubMed ID: 32799325
[TBL] [Abstract][Full Text] [Related]
6. Physician and patient preferences for dosing options in migraine prevention.
Cowan R; Cohen JM; Rosenman E; Iyer R
J Headache Pain; 2019 May; 20(1):50. PubMed ID: 31072307
[TBL] [Abstract][Full Text] [Related]
7. Direct cost and healthcare resource utilization of patients with migraine before treatment initiation with calcitonin gene-related peptide monoclonal antibodies by the number of prior preventive migraine medication classes.
Foster SA; Hoyt M; Ye W; Mason O; Ford JH
Curr Med Res Opin; 2022 May; 38(5):653-660. PubMed ID: 34761723
[TBL] [Abstract][Full Text] [Related]
8. Understanding the migraine treatment landscape prior to the introduction of calcitonin gene-related peptide inhibitors: Results from the Assessment of TolerabiliTy and Effectiveness in MigrAINe Patients using Preventive Treatment (ATTAIN) study.
Kawata AK; Shah N; Poon JL; Shaffer S; Sapra S; Wilcox TK; Shah S; Tepper SJ; Dodick DW; Lipton RB
Headache; 2021 Mar; 61(3):438-454. PubMed ID: 33594686
[TBL] [Abstract][Full Text] [Related]
9. Patient characteristics and treatment utilization among patients with migraine initiating self-injectable calcitonin gene-related peptide monoclonal antibody and novel acute medication.
Varnado OJ; Hoyt M; Ye W; Nicholson R
Curr Med Res Opin; 2022 Aug; 38(8):1451-1457. PubMed ID: 35762152
[TBL] [Abstract][Full Text] [Related]
10. Calcitonin gene-related peptide monoclonal antibody for preventive treatment of episodic migraine: A meta analysis.
Hong P; Wu X; Liu Y
Clin Neurol Neurosurg; 2017 Mar; 154():74-78. PubMed ID: 28129635
[TBL] [Abstract][Full Text] [Related]
11. Calcitonin gene-related peptide (CGRP)-targeted therapies as preventive and acute treatments for migraine-The monoclonal antibodies and gepants.
Chiang CC; Schwedt TJ
Prog Brain Res; 2020; 255():143-170. PubMed ID: 33008505
[TBL] [Abstract][Full Text] [Related]
12. Patient Perspectives and Experiences of Preventive Treatments and Self-Injectable Devices for Migraine: A Focus Group Study.
Seo J; Smith CA; Thomas C; Tervonen T; Hareendran A; Ford JH; Stauffer VL; Nicholson RA; Duffy KH; Tockhorn-Heidenreich A
Patient; 2022 Jan; 15(1):93-108. PubMed ID: 34131880
[TBL] [Abstract][Full Text] [Related]
13. Preferences for preventive treatments for rheumatoid arthritis: discrete choice survey in the UK, Germany and Romania.
Simons G; Veldwijk J; DiSantostefano RL; Englbrecht M; Radawski C; Bywall KS; Valor Méndez L; Hauber B; Raza K; Falahee M
Rheumatology (Oxford); 2023 Feb; 62(2):596-605. PubMed ID: 36068022
[TBL] [Abstract][Full Text] [Related]
14. Fremanezumab for the preventive treatment of migraine.
Silberstein SD; Cohen JM; Yeung PP
Expert Opin Biol Ther; 2019 Aug; 19(8):763-771. PubMed ID: 31177856
[No Abstract] [Full Text] [Related]
15. History and Review of anti-Calcitonin Gene-Related Peptide (CGRP) Therapies: From Translational Research to Treatment.
Tepper SJ
Headache; 2018 Nov; 58 Suppl 3():238-275. PubMed ID: 30242830
[TBL] [Abstract][Full Text] [Related]
16. Real-World experience of interictal burden and treatment in migraine: a qualitative interview study.
Lo SH; Gallop K; Smith T; Powell L; Johnston K; Hubig LT; Williams E; Coric V; Harris L; L'Italien G; Lloyd AJ
J Headache Pain; 2022 Jun; 23(1):65. PubMed ID: 35676636
[TBL] [Abstract][Full Text] [Related]
17. CGRP ligand and receptor monoclonal antibodies for migraine prevention: Evidence review and clinical implications.
Dodick DW
Cephalalgia; 2019 Mar; 39(3):445-458. PubMed ID: 30661365
[TBL] [Abstract][Full Text] [Related]
18. Measuring interictal burden among people affected by migraine: a descriptive survey study.
Hubig LT; Smith T; Williams E; Powell L; Johnston K; Harris L; L'Italien G; Coric V; Lloyd AJ; Lo SH
J Headache Pain; 2022 Aug; 23(1):97. PubMed ID: 35941572
[TBL] [Abstract][Full Text] [Related]
19. Fremanezumab: a disease-specific option for the preventive treatment of migraine, including difficult-to-treat migraine.
Friedman DI; Cohen JM
Emerg Top Life Sci; 2020 Sep; 4(2):179-190. PubMed ID: 32832978
[TBL] [Abstract][Full Text] [Related]
20. Role of Monoclonal Antibodies against Calcitonin Gene-Related Peptide (CGRP) in Episodic Migraine Prevention: Where Do We Stand Today?
Nagaraj K; Vandenbussche N; Goadsby PJ
Neurol India; 2021; 69(Supplement):S59-S66. PubMed ID: 34003149
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
